Contribution of immunohistochemistry to the assessment of prognostic and predictive factors of breast cancer and to the diagnosis of mammary lesions;Contribuição da imuno-histoquímica na avaliação de fatores prognósticos e preditivos do câncer de mama e no diagnóstico de lesões mamárias

Jornal Brasileiro de Patologia e Medicina Laboratorial

Volumn 45, Issue 3, 2009, Pages 213-222

  De Almeida Salles, Mareio ^a,d   Cúrcio, Vinícius Silva ^b   Perez, Amanda Arantes ^c   Gomes, Douglas Soltau ^d   Gobbi, Helenice ^b,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Mamária Faculdade de Medicina UFMG   (Brazil)

^c Ministério de Ciência Tecnologia e Inovação Salvador   (Brazil)

^d UFMG   (Brazil)

Author keywords

Breast; Carcinoma; Diagnosis; Immunohistochemistry; Pathology; Prognostic factors

Indexed keywords

EID: 69949084462     PISSN: 16762444     EISSN: 16784774     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. 1. ALLRED, D. C. et al. Prognostic and predictive factors in breast cancer by imnunohistochemical analysis. Mod Pathol, v. 11, n. 2, p. 155-168, 1998. (Pubitemid 28144151)
2. ALVES, V. A. F. et al. Controle de qualidade interlaboratorial em imuno-histoquímica: citoceratinas e receptor de estrógeno como modelos. J Bras Patol Med Lab, v. 40, n. 3, p.175-183, 2004.
3. BETINA, W. et al. Uso prático da imuno-histoquímica em patologia cirúrgica. J Bras Patol Med Lab, v. 41, n. 5, p.353-364, 2005.
4. 4. BHARGAVA, R., DABBS D. J. Use of immunohistochemistry in diagnosis of breast epithelial lesions. Adv Anat Pathol, v. 14, n. 2, p. 93-107, 2007. (Pubitemid 46673284)
5. 5. CAREY, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama, v. 295, n. 21, p. 2492-2502, 2006. (Pubitemid 43854964)
6. 6. CARTER, B. A. I. Benign transport of breast epithelium into axillary lymph node after biopsy. Am J Clin Pathol, v. 113, n.2, p. 259-265, 2000. (Pubitemid 30212557)
7. CHEANG, M. C. U. et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol, v. 24, n. 36, p. 5637-5644, 2006.
8. DAKO. Dako Herceptest™: a manual for interpretation. Carpinteria: Dako, Manual Guideline, 1999.
9. 9. DA SILVA, L. et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol, v. 32, n. 5, p. 773-783, 2008. (Pubitemid 351600817)
10. DOUGLAS-JONES, A. G. et al. Comparison of core estrogen receptor (ER) assay with excised tumour: intratumoral distribuition of ER in breast carcinoma. J Clin Pathol, v. 54, n. 12, p. 951-955, 2001.
11. FADARE, O., TAVASSOLI, F. A. The phenotypic spectrum of basal-like breast cancer: a critical appraisal. Adv Anat Pathol, v. 14, n. 5, p. 358-373, 2007.
12. FITZGIBBONS P. L. et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, v. 124, n. 7, p. 966-978, 2000.
13. GOBBI, H. et al. Preditive factors of breast cancer evaluated by imunohistochemistry. J Bras Patol Med Lab, v. 44, n. 2, p. 127-136, 2008.
14. GOLDHIRSCH,J. H. et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol, v. 16, p. 1569-1583, 2005.
15. GOLDSTEIN, N. S. et al. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol, v. 115, n. 4, p. 534-542, 2001.
16. GOLDSTEIN, N. S. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases? Am J Clin Pathol, v. 118, n. 3, p. 425-434, 2002.
17. GOLDSTEIN, N. S. et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staning of invasive breast carcinoma. Am J Clin Pathol, v. 120, n.l, p. 86-92, 2003.
18. GOUVÊA, A. P. et al. Her-2/neu immunoreactivity in invasive mammary carcinomas: a comparative study using monoclonal and polyclonal antibodies including the HercepTest™. J Bras Patol Med Lab, v. 40, n. 1, p. 27-32, 2004.
19. GOUVÊA, A. P. et al. Selecting antibodies to detect H ER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl lmmunohistochem Mol Morphol, v. 14, n. 1, p. 103-108, 2006.
20. HODI, Z. et al. The reliability of assessment of estrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol, v. 60, n. 3, p. 299-302, 2007.
21. HUANG, W. Y. et al. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol, v. 151, n. 7, p. 703-714, 2000.
22. KESHGEGIAN, A. A., CNAAN, A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki67 and MIB-1. Am J Clin Pathol, v. 104, n. 1, p. 429, 1995.
23. LIVASY, C. A. et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, v. 19, n. 2, p. 264-271, 2006.
24. MANN, G. B. et al. Reliance on hormone receptor assay of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol, v. 23, n. 22, p. 5148-5154, 2005.
25. MARINHO, V. F. Z. et al. Micrometástases de carcinoma da mama em linfonodos axilares: detecção por imunoistoquímica versus hematoxilina e eosina. J Bras Patol Med Lab, v. 40, n.2, p. 127-132, 2004.
26. MARINHO, V. F. Z. et al. Relationship between histologic features of primary breast carcinomas and axillary lymph node micrometastases: detection and prognostic significance. Appl Immunohistochem Mol Morphol, v. 14, n. 4, p. 426-431, 2006.
27. MARINHO, V. F. Z. et al. Marcadores moleculares em câncer de mama preditivos de metástases axilares. Rev Assoc Med Bras, v. 54, n. 3, p. 1-5, 2008.
28. MARINHO, V. F. Z. et al. Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis. BMC Cancer, v. 8, p. 1-9, 2008.
29. 29. MASTRACCI, T. L. et al. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Modern Pathol, v. 18, n. 6, p. 741-751, 2005. (Pubitemid 40780507)
30. NONOGAKI, S. et al. Análise de indicadores internos e externos relevantes à resolutividade diagnóstica em laboratório de referência em imuno-histoquímica. J Bras Patol Med Lab, v. 43, n. 4, p. 297-304, 2007.
31. NUNES C. B. et al. Concordância interobservador na interpretação imuno-histoquímica da superexpressão do Her-2 detectada por cinco diferentes anticorpos em array de carcinomas mamários. J Bras Patol Med Lab, v. 43, n. 5, p. 373-379, 2007.
32. NUNES, C. B. et al. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J Clin Pathol, v. 61, n. 8, p. 934-938, 2008.
33. 33. PAGE, D. L. et al. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat, v. 51, n. 3, p. 195-208, 1998. (Pubitemid 29054554)
34. PAREDES, J. et al. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch, v. 450, n. 1, p. 73-80, 2007.
35. PINDER, T. C. et al. Breast pathology practice: most common problems in a consultation service. Histopathology, v. 47, n. 5, p. 445-457, 2005.
36. RAKHA, E. A. et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology, v. 50, n. 4, p. 434-438, 2007.
37. 37. RAKHA, E. A. et al. Prognostic markers in triple-negative breast cancer. Cancer, v. 109, n. 1, p. 25-32, 2007. (Pubitemid 46120191)
38. 38. RIBEIRO-SILVA, A. et al. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast? Pathol Oncol Res, v. 9, n. 1, p. 20-23, 2003. (Pubitemid 36608897)
39. RICARDO, S. A. et al. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol, v. 60, n. 9, p. 1001-1005, 2007.
40. ROCHA, R. M. et al. A comparison between the novel rabbit monoclonal antibodies (SPl and B644) and mouse antibodies for evaluating estrogen receptor in breast tumors. J Bras Patol Med Lab, v. 43, n. 6, p. 435-440, 2007.
41. ROCHA, R. et al. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry. Pathol Res Pract, v. 204, n. 6, p. 655-662, 2008.
42. SALLES, M. A., et al. Variação interobservador no diagnóstico histopatológico do carcinoma ductal in situ da mama. Rev Bras Ginecol Obstet, v. 27, n. 1, p. 1-6, 2005.
43. SCHENKA, N. G. M. et al. p63 and CD10: Reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol, v. 14, n. 1, p. 71-77, 2006.
44. TAFURI, L. S, ROCHA, G. F, GOBBI, H. Cell cycle related proteins in hyperplasia of usual type in breast specimens of patients with and without breast cancer. BMC Cell Biol, v. 7, p. 1-8, 2006.
45. TAN, L. K. et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol, v. 26, n. 11, p. 1803-1809, 2008.
46. TAYLOR, C. R. Standardization in immunohistochemistry: the role of antigen retrieval in molecular morphology. Biotech Histochem, v. 81, n. 1, p. 3-12, 2006.
47. 47. WALKER, R. A. Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol, v. 61, p. 689-696, 2008. (Pubitemid 351859960)
48. 48. WOLFF, A. C. et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol, v. 25, n. 1, p. 118-145, 2007. (Pubitemid 350003059)
49. YEH, T., MIES, C. Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med, v. 132, n. 3, p. 349-358, 2008.